Azitra (AZTR) Non-Current Deffered Revenue (2024 - 2025)
Azitra (AZTR) reported Non-Current Deffered Revenue of $35435.0 for Q2 2025, up 11.78% on a YoY basis from $31700.0 in Q2 2024, and little changed quarter-over-quarter from $35435.0 in Q1 2025.
Azitra (AZTR) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends
Azitra has reported Non-Current Deffered Revenue for 2 years, with the latest figure at $35435.0 in Q2 2025.
- For the quarter ending Q2 2025, Non-Current Deffered Revenue rose 11.78% year-over-year to $35435.0; the trailing twelve-month figure through Jun 2025 stood at $35435.0 (up 11.78% YoY), and the FY2024 full-year result was $37477.0, changed N/A from the prior year.
- Non-Current Deffered Revenue for Q2 2025 stood at $35435.0, roughly flat from $35435.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $37477.0 in Q3 2024, with the low at $31700.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Azitra | 20,900.00 | 20,900.00 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 35,435.00 |
| Mar 31, 2025 | 35,435.00 |
| Dec 31, 2024 | 37,477.00 |
| Sep 30, 2024 | 37,477.00 |
| Jun 30, 2024 | 31,700.00 |